Revelation Biosciences, Inc. financial data

Symbol
REVB, REVBW on Nasdaq
Industry
Pharmaceutical Preparations
Location
4660 Lajolla Village Drive, Suite 100, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Petra Acquisition Inc. (to 1/11/2022)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 194 % -8.75%
Debt-to-equity 105 % +20.1%
Return On Assets -119 % -691%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.64M shares -73.9%
Common Stock, Shares, Outstanding 1.64M shares -73.9%
Entity Public Float 7.31M USD -45%
Common Stock, Value, Issued 1.64K USD -73.9%
Weighted Average Number of Shares Outstanding, Basic 1.64M shares +558%
Weighted Average Number of Shares Outstanding, Diluted 1.64M shares +558%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.82M USD +124%
General and Administrative Expense 4.7M USD +23.3%
Operating Income (Loss) -9.53M USD -59.6%
Nonoperating Income (Expense) -6.37M USD -177%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -15.9M USD -782%
Earnings Per Share, Basic -47.8 USD/shares +46.6%
Earnings Per Share, Diluted -39.4 USD/shares +59.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.1M USD -23.2%
Assets, Current 12.2M USD -23.6%
Property, Plant and Equipment, Net 70.8K USD -8.81%
Assets 12.3M USD -23.5%
Accounts Payable, Current 1.28M USD +40.2%
Accrued Liabilities, Current 8.45M USD +1601%
Liabilities, Current 11.1M USD +141%
Liabilities 11.1M USD +141%
Retained Earnings (Accumulated Deficit) -36.5M USD -77.1%
Stockholders' Equity Attributable to Parent 1.14M USD -90%
Liabilities and Equity 12.3M USD -23.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.84M USD -80.2%
Net Cash Provided by (Used in) Financing Activities 5.42M USD -61.4%
Net Cash Provided by (Used in) Investing Activities -19.2K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 1.64M shares -73.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.1M USD -23.2%
Deferred Tax Assets, Valuation Allowance 10.5M USD +23.6%
Deferred Tax Assets, Gross 10.5M USD +23.6%
Depreciation 26K USD +3.82%
Payments to Acquire Property, Plant, and Equipment 19.2K USD
Property, Plant and Equipment, Gross 151K USD +14.5%
Deferred Tax Assets, Operating Loss Carryforwards 7.28M USD +32.1%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 37.7M USD +17.6%
Share-based Payment Arrangement, Expense 128K USD -22%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%